1 / 12

Autologous serum eye drops in severe post-LASIK dry eye.

Autologous serum eye drops in severe post-LASIK dry eye. Alberto Arntz MD, Andrea Cruzat MD, Arturo Grau MD. Pontificia Universidad Católica de Chile. The authors have no financial interest in the subject matter of this poster. Autologous serum eye drops are not FDA aproved. Purpose.

axelle
Télécharger la présentation

Autologous serum eye drops in severe post-LASIK dry eye.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Autologous serum eye drops in severe post-LASIK dry eye. Alberto Arntz MD, Andrea Cruzat MD, Arturo Grau MD. Pontificia Universidad Católica de Chile The authors have no financial interest in the subject matter of this poster. Autologous serum eye drops are not FDA aproved.

  2. Purpose To evaluate the efficacy and safety of Autologous Serum eye drops for the treatment of severe post-LASIK dry eye syndrome.

  3. MethodsInclusion Criteria • Patients with no previous dry eye history, who underwent uneventful LASIK and presented severe dry eye signs 4 weeks after surgery in spite of conventional unpreserved artificial tears therapy. • Severe dry eye diagnosis was stablished when the patient met all three criteria: • 2 lines lost of best-spectacle corrected visual acuity (BSCVA). • Corneal fluorescein staining score (FSC) ≥ 1. • Residual astigmatism ≥ 1.0D

  4. 0 No staining 1 Isolated punctate staining 2 Confluent inferior 1/3 corneal surface staining 3 Confluent inferior 1/2 corneal surface staining 4 Diffuse and complete corneal staining MethodsCorneal Fluorescein Staining Score (FSC)

  5. MethodsRecruitment and Follow-up • Recruitment during one year period. • Patients who met inclusion criteria were enrolled after informed consent. • Autologous serum was obtained and prescribed 6 times a day for 1 month. • 3 months follow-up with monthly visits. • Parameters evaluated every visit: Best-corrected visual acuity (BCVA) Residual refractive astigmatism (RA) Corneal fluorescein staining score (FSC) Adverse effects

  6. MethodsAutologous Serum preparation • 100 ml of venous peripheral blood collected and clotted at room temperature for three hours. • Centrifuge for 10 minutes at 3000 rpm. • Supernatant serum extraction and dilution to 20% in balanced salt solution. • Portions of 5 ml aliquoted into sterile dropper bottles, and labelled with name of the patient and date of production. • Bottles stored frozen at -20ºC. • Every bottle used for 1 week, 6 times a day, stored at 6ºC and discarded after that period.

  7. Results • After recruitment period of 1 year, 14 eyes (8 patients) who met the inclusion criteria were enrolled from nearly 500 LASIK procedures. • 100% women. • Mean age: 33 ± 9 yo. • Preoperative spherical equivalent: 2.6 ± 3.5 D ( range +3.7 to -7.75 ). • No adverse effects were observed.

  8. Results BSCVA Change in BSCVA after LASIK surgery. The green and red arrows represent the beginning and the end of the AS period of treatment.

  9. Results Residual Astigmatism (RA) Change in RA after LASIK surgery. The green and red arrows represent the beginning and the end of the AS period of treatment.

  10. Results Fluoresceinic Staining Score (FSC) Change in corneal FSC after LASIK surgery. The green and red arrows represent the beginning and the end of the AS period of treatment.

  11. Pre Post p Residual Astigmatism (diopters) 1.15 ± 0.84 0.63 ± 0.47 Non significant BSCVA 0.55 ± 0.20 0.7±0.12 <0.05 Corneal fluorescein staining score 2.1 ± 1.03 1.1 ± 0.37 <0.005 Results: Main Outcome measures Main outcome measures pre and post autologous serum treatment: BSCVA= best spectacle corrected visual acuity in snellen equivalent; Values presented as media ± standard deviation. P = statistical level of significance.

  12. Conclusions • Our study suggests that autologous serum is a safe and effective alternative that improves visual function and reduces ocular surface damage in severe post-LASIK dry eye unresponsive to conventional non-preserved artificial tears. • A slight regression in the corneal epithelial fluorescein staining score after AS withdrawal suggests that treatment time should be longer than four weeks. • Long prospective doble-blind studies are needed to confirm our study results.

More Related